• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

    53.80 -4.98 (-8.47%)
    Streaming Delayed Price Updated: 1:08 PM EDT, Mar 10, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about CRISPR Therapeutics AG - Common Shares

    < Previous 1 2
    ...
    29 30 31 32 33 34 35 36 Next >
    News headline image
    Benzinga's Top Ratings Upgrades, Downgrades For December 7, 2021 ↗
    Upgrades For CarMax Inc (NYSE: 
    Via Benzinga
    News headline image
    Why CRISPR Therapeutics Stock Sank 12.5% in November ↗
    The gene-editing specialist's share price is now down roughly 54% in 2021. 
    Via The Motley Fool
    News headline image
    Jim Cramer Shares His Thoughts On Chegg, Bristol-Myers Squibb And More ↗
    On CNBC’s "Mad Money Lightning Round," Jim Cramer said with Matterport, Inc. (NASDAQ: 
    Via Benzinga
    News headline image
    Biotech Stocks are Due for a Rally ↗
    There are many rebalancing trades left in your stock portfolio but biotech is in the doldrums. 
    Via Talk Markets
    News headline image
    Do CRISPR Therapeutics and Intellia Face a Big Safety Risk? ↗
    CRISPR gene editing is promising, but there's a risk that it can cause unwanted mutations. 
    Via The Motley Fool
    News headline image
    Better Buy: Vertex Pharmaceuticals vs. CRISPR ↗
    The companies are collaborating on a potential blockbuster. 
    Via The Motley Fool
    News headline image
    Looking for Growth in Small and Mid Cap Life Science Stocks ↗
    2021 is an unusual year for biotech with a “blow-off” February high in speculative small caps. 
    Via Talk Markets
    News headline image
    Being First Is Not Enough For Crispr Therapeutics ↗
    CRSP stock is facing competition and meeting skepticism as the company tries to turn CRISPR-CAS9 into profitable drug therapies. 
    Via InvestorPlace
    News headline image
    Why CRISPR Therapeutics Stock Fell 18.4% in October ↗
    The gene-editing specialist's stock is now down roughly 37% year to date. 
    Via The Motley Fool
    News headline image
    Why Vertex Is Striking Another Gene-Editing Deal With a Company Not Named CRISPR Therapeutics ↗
    Vertex plans to develop gene-editing therapies with Mammoth Biosciences. 
    Via The Motley Fool
    News headline image
    3 Things About CRISPR Therapeutics That Smart Investors Know ↗
    The company's value isn't reflected in typical performance metrics. 
    Via The Motley Fool
    News headline image
    Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021 ↗
    Upgrades Maxim Group upgraded the previous rating for Indaptus Therapeutics Inc (NASDAQ: 
    Via Benzinga
    News headline image
    2 Gene-Editing Stocks to Have on Your Radar Right Now ↗
    They only have preclinical candidates for now. But these biotechs could have game-changing gene-editing therapies. 
    Via The Motley Fool
    News headline image
    2 Top Healthcare Stocks That Could Be Bought Out in 2022 ↗
    These two novel-drug makers could be top takeover targets next year. 
    Via The Motley Fool
    News headline image
    If You Invested $3,000 in CRISPR Therapeutics in 2018, This Is How Much You Would Have Today ↗
    The returns haven't been half bad, to say the least. 
    Via The Motley Fool
    News headline image
    Crispr: A Fallen Angel In Gene Editing ↗
    As with most promising biotech companies, investors bid their prices up for CRSP based on its potential for early profits. When the payoff didn't occur on schedule, investors bailed out. Once it... 
    Via Talk Markets
    News headline image
    Market Rally Takes Hold As Leading Stocks Shine; Tesla, Taiwan Semi, Delta In Focus: Weekly Review ↗
    It's a confirmed rally again, with the major indexes rebounding on strong earnings and falling yields. 
    Via Investor's Business Daily
    News headline image
    BZ Chart Of The Day: Is Crisper Therapeutics About To Rally? ↗
    Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) may be form... 
    Via Benzinga
    News headline image
    The Daily Biotech Pulse: Moderna Awaits Adcom Ruling On COVID-19 Booster Shot; Teligent Files For Chapter 11; CFO Transitions at Catalyst Biosciences, CRISPR; Lucid Diagnostics Debuts ↗
    Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Catalyst Biosciences Announces Resignation Of CFO Catalyst Biosciences, Inc... 
    Via Benzinga
    News headline image
    50 Biggest Movers From Yesterday ↗
    Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares surged 105.1% to close at $14.79 on Wednesday after Oppenheimer initiated coverage on the stock with an Outperform rating... 
    Via Benzinga
    News headline image
    CRSP Stock: The Cancer Study News Sending Crispr Therapeutics Lower Today ↗
    Crispr Therapeutics (CRSP) stock is falling on Wednesday following the release of new results from a Phase 1 clinical trial. 
    Via InvestorPlace
    News headline image
    40 Stocks Moving In Wednesday's Mid-Day Session ↗
    Gainers Jasper Therapeutics, Inc. (NASDAQ: JSPR) shares jumped 113% to $15.36 after Oppenheimer initiated coverage on the stock with an Outperform rating and a $21 price target... 
    Via Benzinga
    News headline image
    Why CRISPR Therapeutics Stock Is Sinking Today ↗
    Investors aren't impressed with the early-stage results from the biotech's lead cancer therapy candidate. 
    Via The Motley Fool
    News headline image
    Why CRISPR Therapeutics Stock Is Tumbling Today ↗
    CRISPR Therapeutics AG (NASDAQ: CRSP) is trading lower Wednesday after the company reported results from its Phase 1 CARBON trial of CTX110 in relapsed or refractory CD19+ B-... 
    Via Benzinga
    News headline image
    The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal ↗
    Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the... 
    Via Benzinga
    News headline image
    20 Stocks Moving in Wednesday's Pre-Market Session ↗
    Gainers Puxin Limited (NYSE: NEW) rose 52.1% to $0.6901 in pre-market trading after dipping 24% on Tuesday. Jasper Therapeutics, Inc. (NASDAQ: JSPR) rose 38% to $9.95 in pre-... 
    Via Benzinga
    News headline image
    Will Crispr Stock — And Its Cancer Drug — Rise After Allogene's Massive Fall? ↗
    Crispr is planning to begin a registrational test in the first quarter of 2022. 
    Via Investor's Business Daily
    News headline image
    The Week Ahead In Biotech (Oct. 10-16): Avadel FDA Decision, Conference Presentations And IPOs Take Center Stage ↗
    Biotech stocks retreated in the week ending Oct. 8, extending losses for the third straight week. Some of the selling in the space was due to money moving out of defensive... 
    Via Benzinga
    News headline image
    The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology ↗
    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 11) AstraZeneca Plc (NASDAQ:... 
    Via Benzinga
    News headline image
    Why CRISPR Therapeutics Stock Fell 10.4% Last Month ↗
    CRISPR Therapeutics stock is now down roughly 33% across 2021's trading. 
    Via The Motley Fool
    < Previous 1 2
    ...
    29 30 31 32 33 34 35 36 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.